Compare iShares MSCI Japan ETF (EWJ) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Nuwellis Inc — how do they compare? iShares MSCI Japan ETF trades at $97.46 (market cap $23.87B), while Nuwellis Inc trades at $0.7 (market cap $2.20M). The key difference: iShares MSCI Japan ETF is far larger — about 10850× Nuwellis Inc's market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and Nuwellis Inc for 26 Days on average.
| EWJ | NUWE | |
|---|---|---|
Market Cap | $23.87B | $2.20M |
Volume | 5,412,820 | 121,544 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $146.65 |
52-Week Low | $78.36 | $0.68 |
Typical Hold Time | 56 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.44, down 0.9% on the day amid mixed technical signals. The ETF shows neutral momentum with RSI readings around 50 and faces immediate resistance at $98. Recent news highlights Japan's monetary policy uncertainty as the Bank of Japan navigates rate hikes while facing fiscal challenges and yen volatility.
The outlook remains balanced with international ETF performance showing strength but Japanese equities facing headwinds from rising yields and currency pressures. Key risks include BOJ policy missteps and global bond market volatility, while potential catalysts include sustained international diversification trends and yen stabilization efforts.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
